ArticleThyroid research2026
Bilaterality in papillary thyroid carcinoma: long-term outcomes and predictive factors.
Article in Thyroid research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
purposeBilaterality in papillary thyroid carcinoma (PTC) is a critical factor influencing surgical approach selection. This study aimed to investigate the long-term outcomes and predictive factors associated with bilaterality in PTC.
methodsThis retrospective study reviewed 2,816 consecutive PTC patients who underwent total thyroidectomy between January 2013 and December 2015. Risk factors for bilaterality were analyzed using multivariate logistic regression. Among these, 1282 patients with ≥ 24-months follow-up were included in further recurrence/persistence analysis. The primary outcome measured was recurrence-free survival (RFS).
resultsBilaterality was significantly associated with shorter RFS compared to unilateral PTC (p < 0.01), with a mean follow-up of 74.3 ± 33.3 months (median: 71 months; range: 24–140 months). Additionally, multifocality (OR = 4.58, p < 0.01), advanced N stage (N1a: OR = 1.36, p = 0.002; N1b: OR = 1.61, p < 0.01), obesity (OR = 1.74, p < 0.01), and a family history of thyroid cancer (OR = 2.16, p < 0.01) were independent predictors of bilaterality.
conclusionA comprehensive preoperative examination should be conducted to detect bilaterality, particularly in PTC patients with identified risk factors. Additionally, intensive postoperative follow-up is recommended for patients with bilaterality to monitor for recurrence/persistence.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.